论文部分内容阅读
【目的】探讨乳腺癌内分泌治疗失败的原因，为制订临床治疗方案提供参考。【方法】选取2011年1月至2013年12月确诊为乳腺癌并在本院治疗的62例患者的临床资料进行回顾性分析。所有患者术后均行相同方案的内分泌治疗而失败，观察并总结失败的发生率和原因，并进行统计学分析。【结果】62例患者中20例治疗失败，发生率为32．3％。年龄＞45岁、绝经后、表皮生长因子受体‐2（HER‐2）、雌激素受体（ER）磷酸化抗体阳性和类固醇受体辅助活化因子（SRC）表达阳性患者治疗失败率明显升高（ P ＜0．05）。【结论】年龄、绝经、HER‐2、ER磷酸化抗体阳性和SRC表达与乳腺癌内分泌治疗效果有明显的相关性。“,”[Objective] To explore the reasons for a failure of endocrine therapy for breast cancer and pro‐vide rationales for clinical therapeutics .[Methods] From January 2008 to December 2010 ,the clinical data were retrospectively analyzed for 62 cases of breast cancer at our hospital .They received the same scheme of failed endocrine therapy .And the incidence and causes of failure were observed ,summarized and statistically analyzed .[Results] The incidence of failure was 32 .3% .Age >45 years ,postmenopause ,epidermal growth factor receptor‐2 (HER‐2) ,positive phosphorylation of estrogen receptor (ER) antibody and steroid receptor coactivator (SRC) were associated with a significantly elevated rate of treatment failure ( P<0 .05) .[Conclu‐sion] Age ,menopause ,HER‐2 ,positive phosphorylation of ER antibody and SRC are significantly associated with the outcomes of breast cancer endocrine therapy .